US · FMS · MEDICAL - CARE FACILITIES
Fresenius Medical Care AG & Co. KGaA (FMS) intrinsic value and stock valuation
$20.44as of 2026-11-21 · Mkt cap 12.83B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Fresenius Medical Care AG & Co. KGaA DCF and intrinsic value
InvestorsCraft values FMS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from FMS’s statements →
Fresenius Medical Care AG & Co. KGaA Graham Number
Graham Number: $30.45d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Royalty Pharma plc (RPRX) $68.45
- Tenet Healthcare Corporation (THC) $263.19
- Solventum Corporation (SOLV) $84.50
- Smith & Nephew plc (SNN) $29.83
- ICON Public Limited Company (ICLR) $186.71
- DaVita Inc. (DVA) $161.03
- Encompass Health Corporation (EHC) $133.65
- Universal Health Services, Inc. (UHS) $179.43
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $19.6B | $19.3B | $19.5B | $19.4B | $17.6B |
| Operating income | $1.83B | $1.47B | $1.37B | $1.51B | $1.85B |
| Net income | $978.4M | $537.9M | $499M | $673.4M | $969.3M |
| EPSd | $1.68M | $916.6K | $850.3K | $574.1K | $827.2K |
| Operating cash flow | $2.58B | $2.39B | $2.63B | $2.17B | $2.49B |
| Capital expenditure | -$-879.24M | -$-699.36M | -$-684.6M | -$-723.99M | -$-854.36M |
| Free cash flow | $1.7B | $1.69B | $1.94B | $1.44B | $1.64B |
| Total assets | $31B | $33.6B | $33.9B | $35.8B | $34.4B |
| Total debt | $10.8B | $11B | $12.1B | $13.2B | $13.3B |
| Net debt | $9.2B | $9.82B | $10.7B | $11.9B | $11.8B |
| Total equity | $14.3B | $15.8B | $14.8B | $15.4B | $14B |
| Cash and short-term investments | $1.6B | $1.34B | $1.56B | $1.46B | $1.64B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $19.6B | $19.3B | $19.5B | $19.4B | $17.6B |
| Cost of revenue | $14.6B | $14.6B | $14.5B | $14.5B | $12.8B |
| Gross profit | $5.03B | $4.76B | $4.93B | $4.89B | $4.77B |
| Research and development expenses | $158M | $183.5M | $232M | $228.6M | $220.8M |
| Selling, general and administrative expenses | $3.03B | $3.14B | $3.2B | $3.17B | $2.77B |
| Other expenses | $11.4M | -$-37.04M | $127.3M | -$-17.06M | -$-72.87M |
| Operating expenses | $3.2B | $3.29B | $3.56B | $3.38B | $2.92B |
| Cost and expenses | $17.8B | $17.9B | $18.1B | $17.9B | $15.8B |
| Interest income | $69.6M | $71.6M | $88.2M | $67.7M | $73.2M |
| Interest expense | $384.4M | $407M | $424.6M | $360.1M | $353.6M |
| Depreciation and amortization | $1.5B | $1.74B | $1.75B | $1.84B | $1.62B |
| Ebitda | $3.4B | $3.21B | $3.21B | $3.42B | $3.55B |
| Operating income | $1.83B | $1.47B | $1.37B | $1.51B | $1.85B |
| Total other income/expenses, net | -$-314.59M | -$-410.45M | -$-336.42M | -$-292.48M | -$-280.43M |
| Income before tax | $1.51B | $1.06B | $1.03B | $1.22B | $1.57B |
| Income tax expense | $321M | $316.1M | $300.6M | $325M | $352.8M |
| Net income | $978.4M | $537.9M | $499M | $673.4M | $969.3M |
| Weighted average shares outstanding | $582.4M | $587.9M | $587.1M | $1.17B | $1.17B |
| Weighted average diluted shares outstanding | $582.4M | $586.8M | $586.8M | $1.17B | $1.17B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.6B | $1.34B | $1.56B | $1.46B | $1.64B |
| Net receivables | $3.14B | $3.41B | $3.64B | $3.72B | $3.58B |
| Inventory | $2.14B | $2.07B | $2.18B | $2.3B | $2.04B |
| Total current assets | $7.9B | $7.92B | $8.7B | $8.2B | $7.97B |
| Property, plant and equipment, net | $3.01B | $7.26B | $7.45B | $8.34B | $8.55B |
| Goodwill and intangible assets | $14.8B | $16.5B | $16B | $17.3B | $15.8B |
| Long-term investments | $0.00 | $1.12B | $1.08B | $1.2B | $786.9M |
| Total non-current assets | $23.1B | $25.6B | $25.2B | $27.6B | $26.4B |
| Total assets | $31B | $33.6B | $33.9B | $35.8B | $34.4B |
| Accounts payable | $738M | $984.3M | $885.2M | $951.6M | $857.5M |
| Short-term debt | $2.2B | $1.22B | $1.56B | $2.02B | $2.59B |
| Deferred revenue | $0.00 | $82.2M | $85.8M | $105.7M | $518M |
| Total current liabilities | $6.25B | $5.66B | $6.11B | $6.47B | $7.26B |
| Long-term debt | $8.6B | $9.76B | $10.5B | $11.2B | $10.7B |
| Deferred revenue, non-current | $0.00 | $34M | $13.9M | $9.47M | $0.00 |
| Total non-current liabilities | $10.5B | $12.1B | $13B | $13.8B | $13.1B |
| Capital lease obligations | $3.49B | $4.14B | $4.15B | $4.68B | $4.75B |
| Total liabilities | $16.7B | $17.8B | $19.1B | $20.3B | $20.4B |
| Common stock | $14.3B | $293.4M | $293.4M | $293.4M | $293M |
| Retained earnings | $0.00 | $11.3B | $10.9B | $10.7B | $10.8B |
| Accumulated other comprehensive income (loss) | $0.00 | -$-328.55M | -$-975.17M | -$-388.47M | -$-1.31B |
| Total equity | $14.3B | $15.8B | $14.8B | $15.4B | $14B |
| Total investments | $0.00 | $1.29B | $1.23B | $1.39B | $946.1M |
| Total debt | $10.8B | $11B | $12.1B | $13.2B | $13.3B |
| Net debt | $9.2B | $9.82B | $10.7B | $11.9B | $11.8B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $939.8M | $740.9M | $732.5M | $894.3M | $1.22B |
| Depreciation and amortization | $1.41B | $1.74B | $1.75B | $1.84B | $1.62B |
| Stock-based compensation | $0.00 | $0.00 | $32.5M | $0.00 | $0.00 |
| Change in working capital | $132.8M | $444.3M | $561.3M | -$-128.07M | -$-97.77M |
| Accounts receivable | -$-66.34M | -$-73.48M | -$-151.84M | -$-46.68M | -$-163.2M |
| Inventory | -$-238.84M | $107.9M | -$-13.14M | -$-204.31M | -$-48.53M |
| Accounts payable | -$-14.18M | $155.6M | $108.5M | -$-356.79M | -$-363.95M |
| Net cash provided by operating activities | $2.58B | $2.39B | $2.63B | $2.17B | $2.49B |
| Investments in property, plant and equipment | -$-883.73M | -$-699.36M | -$-684.6M | -$-723.99M | -$-854.36M |
| Acquisitions, net | $223.3M | $606.7M | $137M | $1.03M | -$-381.73M |
| Net cash used for investing activities | -$-666.18M | -$-84.94M | -$-544.23M | -$-734.73M | -$-1.2B |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-562.19M | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | -$-405.84M | -$-349.16M | -$-328.62M | -$-395.56M | -$-392.45M |
| Net cash used for financing activities | -$-1.38B | -$-2.57B | -$-1.86B | -$-1.62B | -$-1.02B |
| Net change in cash | $558.3M | -$-241.9M | $153.4M | -$-207.87M | $400.1M |
| Cash at end of period | $1.6B | $1.19B | $1.43B | $1.27B | $1.48B |
| Operating cash flow | $2.58B | $2.39B | $2.63B | $2.17B | $2.49B |
| Capital expenditure | -$-879.24M | -$-699.36M | -$-684.6M | -$-723.99M | -$-854.36M |
| Free cash flow | $1.7B | $1.69B | $1.94B | $1.44B | $1.64B |
Line items
Line items
Line items
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
- CEO
- Helen Giza
- Employees
- 108.17K
- Beta
- 0.76
Explore
Frequently asked questions
What is the intrinsic value of Fresenius Medical Care AG & Co. KGaA (FMS)?
Fresenius Medical Care AG & Co. KGaA (FMS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is FMS undervalued?
FMS trades at a price of $20.44 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.